Breakthrough: Base Editing Reverses Severe Genetic Epilepsy

Researchers at the University of Virginia School of Medicine have used base editing to correct a genetic mutation responsible for a severe form of inherited epilepsy in laboratory mice. This approach targets the root cause of the disease rather than treating the resulting symptoms, potentially offering a path toward a functional cure for certain genetic neurological conditions.

The study focused on SCN8A developmental and epileptic encephalopathy (DEE), a rare inherited disorder that affects approximately 1 in 56,000 births, accounting for roughly 1% of all epilepsies. This condition is characterized by relentless seizures, movement and learning difficulties and a high risk of sudden unexpected death in epilepsy (SUDEP).

The Role of the SCN8A Gene

The SCN8A gene is responsible for encoding a critical sodium channel that regulates how neurons fire by controlling the influx of sodium ions. In patients with SCN8A-related epilepsy, mutations in this gene cause aberrant sodium flow, which leads to hyperactive neurons and the manifestation of intractable seizures and neurological decline.

Traditional medical interventions for this condition have primarily relied on antiepileptic drugs to manage symptoms. However, these symptomatic treatments often fail in SCN8A cases due to medication-resistant epileptogenesis.

Precision Through Base Editing

The research team, led by Dr. Manoj Patel of the UVA Brain Institute and the Department of Anesthesiology, utilized base editing to address the mutation at the nucleotide level. Base editing is a refined form of gene editing that allows for single-base changes in DNA without inducing double-strand breaks.

By avoiding double-strand breaks, the researchers minimized the genomic instability and off-target effects that are more commonly associated with earlier CRISPR methodologies. The high precision of this technique allows scientists to avoid unwanted side effects that can accompany other forms of gene editing.

In the lab mice models, this precision correction of the DNA change effectively eliminated the root cause of the disorder. The findings indicated a reduction in seizures and anxiety-like behaviors in the subjects.

Historically, treatments addressed only the downstream effects of genetic mutations; today, we can correct the mutations themselves, targeting the root cause of disease,

Manoj Patel, UVA Department of Anesthesiology and the UVA Brain Institute

Implications for Future Treatment

The ability to correct disease-causing mutations directly suggests a new trajectory for treating severe genetic epilepsies and other inherited conditions. Dr. Patel noted that base editing has the potential to improve the quality of life for patients by opening the door to the treatment of numerous genetic diseases beyond those associated with epilepsy.

Despite the success in mouse models, the transition to human treatment requires further verification. Dr. Patel has stated that more research is needed before these gene therapy advances can be used in people.

The research was supported by several organizations, including:

• The National Institutes of Health
• The UVA Brain Institute
• The Ivy Biomedical Innovation Fund